Skip to main content
    A

    AbbVie Inc (ABBV)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE

    $294.64
    -0.39 (-0.13%)

    Market Cap: $521.50B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    AbbVie Inc (ABBV) Earnings: Report Dates and Results

    Updated Oct 30, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    AbbVie (ABBV) is expected to report earnings on Feb 2, 2027. In the quarter ended Sep 30, 2026, AbbVie reported EPS of $3.82, above the $3.74 estimate. It beat the EPS estimate in 7 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    88%(35/40)
    Avg Surprise
    +2.23%
    Streak
    2 Q

    Upcoming Estimates

    Reports Feb 2, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$3.95
    Range$3.73 - $4.21
    26 analysts
    Revenue Consensus
    $18.78B
    Range$17.96B - $19.40B
    25 analysts
    Reports Apr 27, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$3.44
    Range$3.31 - $3.90
    9 analysts
    EPS Revisions
    3
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$3.34+2.8%
    60d ago$3.34+2.8%
    30d ago$3.34+3.0%
    7d ago$3.33+3.2%
    Current$3.44
    Revenue Consensus
    $16.43B
    Range$15.89B - $17.20B
    6 analysts

    Next Report

    ABBV has an expected report date of Feb 2, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 45.8% above the $2.71 reported for the quarter ended Dec 31, 2025.

    ABBV Earnings Call

    The latest ABBV earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, ABBV beat 35, missed 4 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $17.40B, up 10.3% from $15.78B a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$3.82$3.74$3.61 - $3.86+2.14%Beat+105.4%220 up, 8 downOct 30, 2026$17.40B
    Jun 30, 2026$3.65$3.64$3.54 - $3.71+0.27%Beat+22.9%221 up, 1 downJul 31, 2026$16.99B
    Mar 31, 2026$2.65$2.67$2.57 - $3.01-0.75%Miss+7.7%230 up, 15 downApr 29, 2026$15.00B
    Dec 31, 2025$2.71$2.65$2.62 - $2.77+2.26%Beat+25.5%170 up, 13 downFeb 4, 2026$16.62B
    Sep 30, 2025$1.86$1.78$1.67 - $1.98+4.49%Beat-38.0%180 up, 14 downOct 31, 2025$15.78B
    Jun 30, 2025$2.97$2.91$2.82 - $3.19+2.06%Beat+12.1%200 up, 14 downJul 31, 2025$15.42B
    Mar 31, 2025$2.46$2.40$2.34 - $2.53+2.50%Beat+6.5%181 up, 4 downApr 25, 2025$13.34B
    Dec 31, 2024$2.16$2.12$2.06 - $2.98+1.89%Beat-22.6%180 up, 6 downJan 31, 2025$15.10B
    Sep 30, 2024$3.00$2.92$2.88 - $2.96+2.74%Beat+1.7%180 up, 1 downOct 30, 2024$14.46B
    Jun 30, 2024$2.65$2.66N/A-0.38%Miss-8.9%180 up, 3 downJul 25, 2024$14.46B
    Mar 31, 2024$2.31$2.23$2.18 - $2.30+3.59%Beat-6.1%131 up, 3 downApr 26, 2024$12.31B
    Dec 31, 2023$2.79$2.77$2.71 - $2.94+0.72%Beat-22.5%171 up, 6 downFeb 2, 2024$14.30B
    Sep 30, 2023$2.95$2.87N/A+2.79%Beat-19.4%173 up, 1 downOct 27, 2023$13.93B
    Jun 30, 2023$2.91$2.81$2.76 - $2.89+3.56%Beat-13.6%161 up, 3 downJul 27, 2023$13.87B
    Mar 31, 2023$2.46$2.49$2.36 - $2.64-1.20%Miss-22.2%144 up, 2 downApr 27, 2023$12.22B
    Dec 31, 2022$3.60$3.58$3.51 - $3.66+0.56%Beat+8.8%172 up, 1 downFeb 9, 2023$15.12B
    Sep 30, 2022$3.66$3.57$3.51 - $3.70+2.52%Beat+9.9%152 up, 1 downOct 28, 2022$14.81B
    Jun 30, 2022$3.37$3.31$3.21 - $3.49+1.81%Beat+8.4%151 up, 3 downJul 29, 2022$14.58B
    Mar 31, 2022$3.16$3.14$3.10 - $3.20+0.64%Beat+7.1%165 up, 1 downApr 29, 2022$13.54B
    Dec 31, 2021$3.31$3.28$3.21 - $3.39+0.91%Beat+13.4%166 up, 2 downFeb 2, 2022$14.89B
    Sep 30, 2021$3.33$3.22$3.13 - $3.27+3.42%Beat+17.7%13N/AOct 29, 2021$14.34B
    Jun 30, 2021$3.11$3.03N/A+2.64%Beat+32.9%16N/AJul 30, 2021$13.96B
    Mar 31, 2021$2.95$2.83$2.76 - $3.02+4.24%Beat+21.9%16N/AApr 30, 2021$13.01B
    Dec 31, 2020$2.92$2.85$2.74 - $2.90+2.46%Beat+32.1%18N/AFeb 3, 2021$13.86B
    Sep 30, 2020$2.83$2.77$2.70 - $2.88+2.17%Beat+21.5%15N/AOct 30, 2020$12.90B
    Jun 30, 2020$2.34$2.20$1.86 - $2.49+6.36%Beat+3.5%11N/AJul 31, 2020$10.43B
    Mar 31, 2020$2.42$2.25$2.01 - $2.31+7.56%Beat+13.1%11N/AMay 1, 2020$8.62B
    Dec 31, 2019$2.21$2.19$2.17 - $2.22+0.91%Beat+16.3%10N/AFeb 7, 2020$8.70B
    Sep 30, 2019$2.33$2.30$2.23 - $2.36+1.30%Beat+8.9%8N/ANov 1, 2019$8.48B
    Jun 30, 2019$2.26$2.21$2.19 - $2.23+2.26%Beat+13.0%9N/AJul 26, 2019$8.26B
    Mar 31, 2019$2.14$2.07$2.01 - $2.10+3.38%Beat+14.4%15N/AApr 25, 2019$7.83B
    Dec 31, 2018$1.90$1.93$1.86 - $2.03-1.55%Miss+28.4%13N/AJan 25, 2019$8.30B
    Sep 30, 2018$2.14$2.00$1.93 - $2.06+7.00%Beat+51.8%17N/ANov 2, 2018$8.24B
    Jun 30, 2018$2.00$1.97$1.91 - $2.05+1.52%Beat+40.8%17N/AJul 27, 2018$8.28B
    Mar 31, 2018$1.87$1.79$1.75 - $1.85+4.47%Beat+46.1%19N/AApr 26, 2018$7.93B
    Dec 31, 2017$1.48$1.43$1.42 - $1.51+3.50%Beat+23.3%16N/AJan 26, 2018$7.74B
    Sep 30, 2017$1.41$1.39$1.36 - $1.42+1.44%Beat+16.5%17N/AOct 27, 2017$7.00B
    Jun 30, 2017$1.42$1.40$1.35 - $1.42+1.43%Beat+12.7%18N/AJul 28, 2017$6.94B
    Mar 31, 2017$1.28$1.26N/A+1.59%Beat+11.3%N/AN/AApr 27, 2017$6.54B
    Dec 31, 2016$1.20$1.20N/A0.00%In line+6.2%N/AN/AJan 27, 2017$6.80B
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $10.00, down 1.2% from the year before. It was $4.82 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$10.00-1.2%
    Dec 31, 2024$10.12-8.9%
    Dec 31, 2023$11.11-19.4%
    Dec 31, 2022$13.79+8.6%
    Dec 31, 2021$12.70+20.8%
    Dec 31, 2020$10.51+17.6%
    Dec 31, 2019$8.94+13.0%
    Dec 31, 2018$7.91+41.5%
    Dec 31, 2017$5.59+16.0%
    Dec 31, 2016$4.82N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 9,800 words across 17 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20269,81917
    2026Q2Jun 30, 20267,24517
    2026Q1Mar 31, 202610,40416
    2025Q4Dec 31, 20259,84617
    2025Q3Sep 30, 202510,37618
    2025Q2Jun 30, 20257,05117
    2025Q1Mar 31, 202511,38820
    2024Q4Dec 31, 20249,17016

    2026Q3 Earnings Call

    Opening remarks

    Elizabeth Shea Senior Vice President, Investor Relations Good morning, and thanks for joining us. Also on the call with me today are Rob Michael, Chairman and Chief Executive Officer; Jeff Stewart, Executive Vice President, Chief Commercial Officer; Roopal Thakkar, Executive Vice President, Research and Development, Chief Scientific Officer; and Scott Reents, Executive Vice President, Chief Financial Officer. Before we get started, I'll note that some statements we make today may be considered forward-looking statements based on our current expectations. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in our forward-looking statements. Additional information about these risks and uncertainties is included in our SEC filings. AbbVie undertakes no obligation to update these forward-looking statements, except as required by law. On today's conference call, non-GAAP financial measures will be used to help investors understand AbbVie's business performance. These non-GAAP financial measures are reconciled with comparable GAAP financial measures in our earnings release and regulatory filings from today, which can be found on our website. Following our prepared remarks, we'll take your questions. So with that, I'll turn the call over to Rob.

    Robert Michael Chairman and Chief Executive Officer Thank you, Liz. Good morning, everyone, and thank you for joining us. AbbVie continues to perform above our expectations, with another quarter of outstanding results. We are delivering top-tier sales and earnings growth and making significant progress advancing our pipeline. Given the strength of our business and our promising outlook, we are once again raising our full-year guidance and increasing our quarterly dividend. Turning to our third-quarter performance, we achieved adjusted earnings per share of $3.82, which is $0.07 above our guidance midpoint. Total net revenues were $17.4 billion, beating our expectations by $200 million and reflecting robust sales growth of more than 10%. This includes 9 key products that delivered double-digit growth. Based on the strong performance across our business, including Skyrizi, Rinvoq, Vraylar, Ubrelvy, Qulipta and Venclexta, we are raising our full-year revenue guidance by $200 million and have now raised total revenue by $800 million since the start of the year. Further underscoring our confidence in our long-term outlook, today, we announced a 5.2% increase in our quarterly cash dividend, beginning with the dividend payable in February 2027. Since inception, we have grown our quarterly dividend by more than 350%. Turning now to R&D. We are making excellent progress advancing our pipeline to help drive growth in the 2030s and beyond. In immunology, we completed the acquisition of Apogee Therapeutics, adding multiple differentiated assets in dermatology, respiratory and other related inflammatory diseases with significant sales potential. The lead asset, zumilokibart, will be starting Phase III development in atopic dermatitis later this year. Also in immunology, we received U.S.

    Frequently Asked Questions About ABBV

    When is AbbVie's next earnings date?

    AbbVie's next earnings report is expected for Feb 2, 2027.

    Did ABBV beat earnings estimates last quarter?

    Yes. AbbVie reported EPS of $3.82 for the quarter ended Sep 30, 2026, above the $3.74 estimate, a 2.14% surprise.

    What EPS do analysts expect from ABBV next quarter?

    The consensus EPS estimate for AbbVie for the quarter ending Dec 31, 2026 is $3.95 from 26 analysts, with estimates from $3.73 to $4.21.

    How often does ABBV beat earnings estimates?

    AbbVie beat the EPS estimate in 7 of the last 8 quarters, with an average surprise of +1.86%.